Table 2.
Probabilistic cost-effectiveness results.
| Incremental | |||||
|---|---|---|---|---|---|
| CAD | Aspirin | DPI | DPI vs. aspirin | ||
| Costs | €99,807 | €109,941 | €10,134 | ||
| Life years | 11.697 | 12.131 | 0.434 | ||
| QALYs | 7.773 | 8.089 | 0.316 | ||
| ICER | €32,035 | ||||
|
PAD |
Aspirin |
DPI |
Clopidogrel |
Incremental |
Incremental |
|
DPI vs. aspirin |
Clopidogrel vs. aspirin |
||||
| Costs | €156,905 | €166,945 | €165,843 | €10,040 | €8938 |
| Life years | 11.667 | 12.127 | 12.114 | 0.460 | 0.446 |
| QALYs | 7.489 | 7.868 | 7.761 | 0.379 | 0.272 |
| ICER | €26,463 | *€32,913 |
CAD: coronary artery disease; DPI: dual pathway inhibition; ICER: incremental cost-effectiveness ratio; PAD: peripheral arterial disease; QALY: quality-adjusted-life-year.
*Clopidogrel is extendedly dominated, i.e. the ICER of DPI vs. aspirin is lower than the ICER of clopidogrel vs. aspirin.